Collaboration to address product development and scale up challenges posed by current pandemic
Press Release
BASEL, Switzerland, March 26, 2020/3BL Media/ - Today, Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and expertise needed to identify effective and scalable solutions to the pandemic that is affecting billions worldwide.
Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19
Novartis Sandoz division will pursue appropriate regulatory authorizations and, upon approval, will work with stakeholders to determine how best to get this medicine to the patients who need it
Commitment builds on recently announced USD 20 million Novartis COVID19 Response Fund, drug discovery and development collaborations and essential medicines price stability
Novartis encourages industry, governments and international institutions to work together to ensure adequate global access of medications to treat COVID-19 patients
Press Release
Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19
Novartis Sandoz division will pursue appropriate regulatory authorizations and, upon approval, will work with stakeholders to determine how best to get this medicine to the patients who need it
Commitment builds on recently announced USD 20 million Novartis COVID19 Response Fund, drug discovery and development collaborations and essential medicines price stability
Novartis encourages industry, governments and international institutions to work together to ensure adequate global access of medications to treat COVID-19 patients
March 12, 2020 /3BL Media/ - A diverse group of investors, companies, trade associations, institutions, and organizations across the Northeast and Mid-Atlantic are urging the region’s governors today to band together and create a clean transportation future that enables economic growth.
EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million.
The PAMAfrica consortium brings together a global medicines company, a not-for-profit product development partnership and leading academic institutions in Africa and Europe. PAMAfrica aims to develop new medicines for both severe and uncomplicated malaria, designed to combat emerging artemisinin resistance.
The projects will include development of the first new malaria treatment for babies under 5 kg, a new fast-acting medicine for the treatment of severe malaria, and new combinations to treat drug-resistant uncomplicated malaria.
Press Release
EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million.
The PAMAfrica consortium brings together a global medicines company, a not-for-profit product development partnership and leading academic institutions in Africa and Europe. PAMAfrica aims to develop new medicines for both severe and uncomplicated malaria, designed to combat emerging artemisinin resistance.
The projects will include development of the first new malaria treatment for babies under 5 kg, a new fast-acting medicine for the treatment of severe malaria, and new combinations to treat drug-resistant uncomplicated malaria.
At Novartis, our purpose is to reimagine medicine to improve and extend people’s lives. We do this by unleashing the power of our associates to deliver transformative innovation, embrace operational excellence, go big on data and digital and build trust with society. This report highlights our progress in advancing these areas to benefit patients and help strengthen our communities and society.
Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis
LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust
Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic countries, once approved
DNDi will lead Phase II and III clinical development, starting in India with additional trials planned in East Africa
Leishmaniasis, which is transmitted by the sand fly, affects over one billion people; visceral leishmaniasis, the most serious form of the disease, affects an estimated 50 000 to 90 000 people per year
Press Release
Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis
LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust
Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic countries, once approved
DNDi will lead Phase II and III clinical development, starting in India with additional trials planned in East Africa
Leishmaniasis, which is transmitted by the sand fly, affects over one billion people; visceral leishmaniasis, the most serious form of the disease, affects an estimated 50 000 to 90 000 people per year
February 3, 2020 - For the seventh consecutive year, Novartis is publishing an annual Novartis in Society ESG report. The report has been prepared in accordance with the GRI Standards: Core option. It supplements the “Build trust with society” section in the 2019 Novartis Annual Review and the 2019 Novartis Annual Report.
Healthcare companies and philanthropies to fund training of thousands of community health workers as part of larger initiative led by Last Mile Health and Living Goods to advance universal health coverage
Press Release
BASEL, SWITZERLAND/NEW YORK, 16 January 2020 /3BL Media/ – Johnson & Johnson, Lilly, Novartis, Pfizer, GSK and the Bill & Melinda Gates Foundation have joined forces with Last Mile Health and Living Goods to increase access to community-based primary healthcare for nearly 1.7 million people in up to six African countries, as part of their shared commitment to accelerate universal health coverage. The Health Worker Training Initiative is a three-year investment, generously matched by The Audacious Project, and totals USD $18 million.
The fellowships aim to develop the clinical research skills of early to mid-career scientists in sub-Saharan Africa, specifically on the interaction between poverty-related diseases and noncommunicable diseases
Novartis will provide € 750 000 for at least five fellowships over three years; the EDCTP will match this amount
Novartis invests in the training and support of scientists and researchers from developing countries to help expand their knowledge and expertise and improve their ability to contribute to their local communities
Press Release
The fellowships aim to develop the clinical research skills of early to mid-career scientists in sub-Saharan Africa, specifically on the interaction between poverty-related diseases and noncommunicable diseases
Novartis will provide € 750 000 for at least five fellowships over three years; the EDCTP will match this amount
Novartis invests in the training and support of scientists and researchers from developing countries to help expand their knowledge and expertise and improve their ability to contribute to their local communities
Cette stratégie s’inscrit dans la continuité des Novartis Access Principles, qui visent à intégrer systématiquement des stratégies d’accès dans la manière dont l’entreprise recherche, développe et commercialise ses médicaments dans le monde entier
Une unité récemment formée pour l’Afrique subsaharienne déploiera des approches innovantes pour atteindre davantage de patients, sur l’ensemble de la pyramide des revenus
Novartis se base sur ses activités établies dans le domaine du paludisme, du cancer, de la drépanocytose et des maladies cardiovasculaires, ainsi que sur ses modèles d’entreprises sociales qui ont fait leurs preuves sur ce continent
L’Afrique supporte un quart du fardeau mondial des maladies, mais seuls 3% des professionnels de la santé dans le monde sont basés sur ce continent. Par ailleurs, moins de 1% des dépenses de santé mondiales sont réalisées en Afrique1.
Press Release
Cette stratégie s’inscrit dans la continuité des Novartis Access Principles, qui visent à intégrer systématiquement des stratégies d’accès dans la manière dont l’entreprise recherche, développe et commercialise ses médicaments dans le monde entier
Une unité récemment formée pour l’Afrique subsaharienne déploiera des approches innovantes pour atteindre davantage de patients, sur l’ensemble de la pyramide des revenus
Novartis se base sur ses activités établies dans le domaine du paludisme, du cancer, de la drépanocytose et des maladies cardiovasculaires, ainsi que sur ses modèles d’entreprises sociales qui ont fait leurs preuves sur ce continent
L’Afrique supporte un quart du fardeau mondial des maladies, mais seuls 3% des professionnels de la santé dans le monde sont basés sur ce continent. Par ailleurs, moins de 1% des dépenses de santé mondiales sont réalisées en Afrique1.
